Chemotherapy for patients with gastric cancer after complete resection: A network meta-analysis

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 584-592

  Zhang, Ya Wu ^a   Zhang, Yu Long ^a   Pan, Hui ^a   Wei, Feng Xian ^a   Zhang, You Cheng ^a   Shao, Yuan ^a   Han, Wei ^a   Liu, Hai Peng ^a   Wang, Zhe Yuan ^a   Yang, Sun Hu ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Chemotherapy; Gastric cancer; Indirect treatment comparison; Network meta analysis; Randomized controlled trials

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CISPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN; SEMUSTINE; TEGAFUR; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; DRUG EFFICACY; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; GASTRECTOMY; MORTALITY; RISK FACTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; GASTRECTOMY; HUMANS; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84892876543     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.584     Document Type: Article

References (49)

1. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992; 79: 293-299 [PMID: 1576492 DOI: 10.1002/bjs.1800790404]
2. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133 [PMID: 11957056 DOI: 10.1007/s101200050006]
3. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992; 70: 1030-1037 [PMID: 1515980 DOI: 10.1002/1097-0142(19920901)70: 5<1030::AID-CNCR2820700504>3.0.CO;2-C]
4. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002; 5 Suppl 1: 5-11 [PMID: 12772880 DOI: 10.1007/ s10120-002-0203-6]
5. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003; 21: 274s-275s [PMID: 14645409 DOI: 10.1200/JCO.2003.09.172]
6. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242 [PMID: 10671934 DOI: 10.1046/ j.1365-2168.2000.01360]
7. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900 [PMID: 16223826 DOI: 10.1136/bmj.331.7521.897]
8. Fadda V, Maratea D, Trippoli S, Messori A. Network metaanalysis. Results can be summarised in a simple figure. BMJ 2011; 342: d1555 [PMID: 21430004]
9. Fadda V, Maratea D, Trippoli S, Messori A. Treatments for macular degeneration: summarising evidence using network meta-analysis. Br J Ophthalmol 2011; 95: 1476-1477 [PMID: 21680571 DOI: 10.1136/bjophthalmol-2011-300316]
10. Maratea D, Fadda V, Trippoli S, Messori A. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 2011; 9: 1868-1870 [PMID: 21711443 DOI: 10.1111/j.1538-7836.2011.04421]
11. Messori A, Del Santo F, Maratea D. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011; 33: 1383-1385 [PMID: 21569068 DOI: 10.1111/j.1365-2036.2011.04672]
12. Passaro D, Fadda V, Maratea D, Messori A. Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. Int J Cardiol 2011; 150: 364-367 [PMID: 21652097 DOI: 10.1016/j.ijcard.2011.05.083]
13. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168: 597-608 [PMID: 12699095 DOI: 10.1080/11024 150201680005]
14. Liu TS, Wang Y, Chen SY, Sun YH. An updated metaanalysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008; 34: 1208-1216 [PMID: 18353606 DOI: 10.1016/j.ejso.2008.02.002]
15. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843 [PMID: 10997811 DOI: 10.1023/A:1008377101672]
16. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 2006; 18: 311-317 [PMID: 17129844]
17. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737 [PMID: 20442389 DOI: 10.1001/jama.2010.534]
18. Zhao SL, Fang JY. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 2008; 26: 317-325 [PMID: 18317973 DOI: 10.1080/07357900701834686]
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797 DOI: 10.1016/0197-2456(95)00134-4]
20. Lawton JO, Giles GR, Hall R, Bird GG, Matheson T. Chemotherapy following palliative resection of gastric cancer. Br J Surg 1981; 68: 397-399 [PMID: 6165425 DOI: 10.1002/ bjs.1800680610]
21. Stablein DM, Douglass HO. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer[J]. Cancer 1982; 49: 1116-1122 [PMID: 7037156 DOI: 10. 1002/1097-0142(19820315)49:6<1116::AIDCNCR2820490609> 3.0.CO;2-U]
22. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 1983; 52: 1105-1112 [PMID: 6349780 DOI: 10.1002/1097-0142(19830915)52:6<1105::AIDCNCR2820520629> 3.0.CO; 2-Z]
23. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366-1371 [PMID: 6439835]
24. Engstrom PF, Lavin PT, Douglass HO, Brunner KW. Postop-erative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55: 1868-1873 [PMID: 3884131 DOI: 10.1002/1097-0142(19850501)55:9<1868::AIDCNCR2820550904> 3.0.CO; 2-B]
25. Schlag P. Adjuvant chemotherapy in gastric cancer. World J Surg 1987; 11: 473-477 [PMID: 3630192 DOI: 10.1007/ BF01655812]
26. Bonfanti G. Adjuvant treatments following curative resection for gastric cancer[J]. Br J Surg 1988; 75: 1100-1104 [PMID: 2905188]
27. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimalt A. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990; 8: 1362-1369 [PMID: 2199622]
28. Estape J, Grau JJ, Lcobendas F, Curto J, Daniels M, Viñolas N, Pera C. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991; 213: 219-221 [PMID: 1900148 DOI: 10.1097/00000658-199103000-00006]
29. Krook JE, O'Connell MJ, Wieand HS, Beart RW, Leigh JE, Kugler JW, Foley JF, Pfeifle DM, Twito DI. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458 [PMID: 2015545 DOI: 10.1002/1097-0142(19910515)67:10<2454::AIDCNCR2820671010> 3.0.CO; 2-2]
30. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992; 216: 269-278; discussion 278-279 [PMID: 1417176]
31. Grau JJ, Estapé J, Alcobendas F, Pera C, Daniels M, Terés J. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-342 [PMID: 8398330]
32. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312 [PMID: 7910321 DOI: 10.1016/S0140-6736(94)92464-3]
33. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, Mc-Clure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB, Gagliano R. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494 [PMID: 8591078 DOI: 10.1007/BF02307081]
34. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763 [PMID: 7595735]
35. Tsavaris N, Tentas K, Kosmidis P, Mylonakis N, Sakelaropoulos N, Kosmas C, Lisaios B, Soumilas A, Mandrekas D, Tsetis A, Klonaris C. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996; 42: 220-226 [PMID: 8983891 DOI: 10.1159/000239446]
36. Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigí E, Guasch I, Badia A, Boleda M. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815 [PMID: 10577853]
37. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-277 [PMID: 10440302 DOI: 10.1016/S0140-6736(99)01048-X]
38. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, Medi F, Mercatelli A, Romano S, Siliani L, Tarquini R, Moretti R. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001; 84: 878-880 [PMID: 11286464 DOI: 10.1054/bjoc.2000.1472]
39. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307 [PMID: 11886009]
40. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287 [PMID: 12805327]
41. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004; 7: 240-245 [PMID: 15616772]
42. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fagniez PL, Gainant A. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004; 187: 440-445 [PMID: 15006580 DOI: 10.1016/j.amjsurg.2003.12.014]
43. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P; Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488-1497 [PMID: 15939717]
44. Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, Tres A, Coombes RC, Crivellari D, Marchet A, Sanchez E, Bliss JM, Homewood J, Couvreur ML, Hall E, Baron B, Woods E, Emson M, Van Cutsem E, Lise M; EORTC GI Group; ICCG. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006; 17: 262-269 [PMID: 16293676 DOI: 10.1093/annonc/mdj077]
45. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G; Gruppo Oncologico Italia Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602. Study). Ann Oncol 2007; 18: 1354-1358 [PMID: 17525087]
46. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y; National Surgical Adjuvant Study of Gastric Cancer Group. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94: 1468-1476 [PMID: 17948223 DOI: 10.1002/bjs.5996]
47. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008; 100: 388-398 [PMID: 18334706 DOI: 10.1093/jnci/djn054]
48. Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K; Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011; 14: 212-218 [PMID: 21336855 DOI: 10.1007/ s10120-011-0027-3]
49. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393 [PMID: 22010012]